Cargando…
Plasma Level of ADAMTS13 or IL-12 as an Indicator of HBeAg Seroconversion in Chronic Hepatitis B Patients Undergoing m-ETV Treatment
The ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin motif repeats 13) is a key factor involved in coagulation process and plays a vital role in the progression and prognosis of chronic hepatitis B (CHB) patients with antiviral treatment. However, there are few reports about the p...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7393286/ https://www.ncbi.nlm.nih.gov/pubmed/32793509 http://dx.doi.org/10.3389/fcimb.2020.00335 |
_version_ | 1783565012549238784 |
---|---|
author | Yang, Jiezuan Guo, Renyong Yan, Dong Lu, Haifeng Zhang, Hua Ye, Ping Jin, Linfeng Diao, Hongyan Li, Lanjuan |
author_facet | Yang, Jiezuan Guo, Renyong Yan, Dong Lu, Haifeng Zhang, Hua Ye, Ping Jin, Linfeng Diao, Hongyan Li, Lanjuan |
author_sort | Yang, Jiezuan |
collection | PubMed |
description | The ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin motif repeats 13) is a key factor involved in coagulation process and plays a vital role in the progression and prognosis of chronic hepatitis B (CHB) patients with antiviral treatment. However, there are few reports about the profile of plasma ADAMTS13 in CHB patients during entecavir maleate (m-ETV) treatment. One hundred two HBV e antigen (HBeAg)–positive CHB patients on continuous m-ETV naive for at least 96 weeks were recruited. Patients with liver cirrhosis were excluded using liver biopsies and real-time elastography. Plasma ADAMTS13 and interleukin 12 (IL-12) levels were evaluated at baseline and12, 24, 48, 72, and 96 weeks, respectively. The change of ADAMTS13 (ΔADAMTS13) and IL-12 (ΔIL-12) possesses a significant relationship in CHB patients with HBeAg seroconversion (SC) at 48-week m-ETV treatment (p < 0.001), but no significance in patients without SC. Furthermore, Cox multivariate analysis demonstrated that the change of ADAMTS13 (IL-12) is an independent predictor for HBeAg SC at week 96, and the area under the receiver operating characteristic curve for the ΔADAMTS13 (ΔIL-12) in CHB patients with 48-week m- ETV treatment is 0.8204 (0.8354) (p < 0.001, both) to predict HBeAg SC at week 96. The results suggested that higher increased ADAMTS13 and IL-12 after 48-week m-ETV treatment contributed to an enhanced probability of HBeAg SC, although the mechanism is undetermined. Quantification of ADAMTS13 (IL-12) during m-ETV treatment may help to predict long-term HBeAg SC in CHB patients. |
format | Online Article Text |
id | pubmed-7393286 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-73932862020-08-12 Plasma Level of ADAMTS13 or IL-12 as an Indicator of HBeAg Seroconversion in Chronic Hepatitis B Patients Undergoing m-ETV Treatment Yang, Jiezuan Guo, Renyong Yan, Dong Lu, Haifeng Zhang, Hua Ye, Ping Jin, Linfeng Diao, Hongyan Li, Lanjuan Front Cell Infect Microbiol Cellular and Infection Microbiology The ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin motif repeats 13) is a key factor involved in coagulation process and plays a vital role in the progression and prognosis of chronic hepatitis B (CHB) patients with antiviral treatment. However, there are few reports about the profile of plasma ADAMTS13 in CHB patients during entecavir maleate (m-ETV) treatment. One hundred two HBV e antigen (HBeAg)–positive CHB patients on continuous m-ETV naive for at least 96 weeks were recruited. Patients with liver cirrhosis were excluded using liver biopsies and real-time elastography. Plasma ADAMTS13 and interleukin 12 (IL-12) levels were evaluated at baseline and12, 24, 48, 72, and 96 weeks, respectively. The change of ADAMTS13 (ΔADAMTS13) and IL-12 (ΔIL-12) possesses a significant relationship in CHB patients with HBeAg seroconversion (SC) at 48-week m-ETV treatment (p < 0.001), but no significance in patients without SC. Furthermore, Cox multivariate analysis demonstrated that the change of ADAMTS13 (IL-12) is an independent predictor for HBeAg SC at week 96, and the area under the receiver operating characteristic curve for the ΔADAMTS13 (ΔIL-12) in CHB patients with 48-week m- ETV treatment is 0.8204 (0.8354) (p < 0.001, both) to predict HBeAg SC at week 96. The results suggested that higher increased ADAMTS13 and IL-12 after 48-week m-ETV treatment contributed to an enhanced probability of HBeAg SC, although the mechanism is undetermined. Quantification of ADAMTS13 (IL-12) during m-ETV treatment may help to predict long-term HBeAg SC in CHB patients. Frontiers Media S.A. 2020-07-24 /pmc/articles/PMC7393286/ /pubmed/32793509 http://dx.doi.org/10.3389/fcimb.2020.00335 Text en Copyright © 2020 Yang, Guo, Yan, Lu, Zhang, Ye, Jin, Diao and Li. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cellular and Infection Microbiology Yang, Jiezuan Guo, Renyong Yan, Dong Lu, Haifeng Zhang, Hua Ye, Ping Jin, Linfeng Diao, Hongyan Li, Lanjuan Plasma Level of ADAMTS13 or IL-12 as an Indicator of HBeAg Seroconversion in Chronic Hepatitis B Patients Undergoing m-ETV Treatment |
title | Plasma Level of ADAMTS13 or IL-12 as an Indicator of HBeAg Seroconversion in Chronic Hepatitis B Patients Undergoing m-ETV Treatment |
title_full | Plasma Level of ADAMTS13 or IL-12 as an Indicator of HBeAg Seroconversion in Chronic Hepatitis B Patients Undergoing m-ETV Treatment |
title_fullStr | Plasma Level of ADAMTS13 or IL-12 as an Indicator of HBeAg Seroconversion in Chronic Hepatitis B Patients Undergoing m-ETV Treatment |
title_full_unstemmed | Plasma Level of ADAMTS13 or IL-12 as an Indicator of HBeAg Seroconversion in Chronic Hepatitis B Patients Undergoing m-ETV Treatment |
title_short | Plasma Level of ADAMTS13 or IL-12 as an Indicator of HBeAg Seroconversion in Chronic Hepatitis B Patients Undergoing m-ETV Treatment |
title_sort | plasma level of adamts13 or il-12 as an indicator of hbeag seroconversion in chronic hepatitis b patients undergoing m-etv treatment |
topic | Cellular and Infection Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7393286/ https://www.ncbi.nlm.nih.gov/pubmed/32793509 http://dx.doi.org/10.3389/fcimb.2020.00335 |
work_keys_str_mv | AT yangjiezuan plasmalevelofadamts13oril12asanindicatorofhbeagseroconversioninchronichepatitisbpatientsundergoingmetvtreatment AT guorenyong plasmalevelofadamts13oril12asanindicatorofhbeagseroconversioninchronichepatitisbpatientsundergoingmetvtreatment AT yandong plasmalevelofadamts13oril12asanindicatorofhbeagseroconversioninchronichepatitisbpatientsundergoingmetvtreatment AT luhaifeng plasmalevelofadamts13oril12asanindicatorofhbeagseroconversioninchronichepatitisbpatientsundergoingmetvtreatment AT zhanghua plasmalevelofadamts13oril12asanindicatorofhbeagseroconversioninchronichepatitisbpatientsundergoingmetvtreatment AT yeping plasmalevelofadamts13oril12asanindicatorofhbeagseroconversioninchronichepatitisbpatientsundergoingmetvtreatment AT jinlinfeng plasmalevelofadamts13oril12asanindicatorofhbeagseroconversioninchronichepatitisbpatientsundergoingmetvtreatment AT diaohongyan plasmalevelofadamts13oril12asanindicatorofhbeagseroconversioninchronichepatitisbpatientsundergoingmetvtreatment AT lilanjuan plasmalevelofadamts13oril12asanindicatorofhbeagseroconversioninchronichepatitisbpatientsundergoingmetvtreatment |